Actualización en el uso del PET/CT en sarcoma de Ewing, a propósito de un caso

dc.creatorBarahona Z., Daniela
dc.creatorAdlerstein L., Isabel
dc.creatorFaure R., María Ignacia
dc.date.accessioned2021-08-25T16:56:19Z
dc.date.accessioned2023-05-19T14:50:17Z
dc.date.available2021-08-25T16:56:19Z
dc.date.available2023-05-19T14:50:17Z
dc.date.created2021-08-25T16:56:19Z
dc.date.issued2020
dc.identifierRevista Médica de Chile 2020; 148: 1504-1507
dc.identifierhttp://dx.doi.org/10.4067/S0034-98872020001001504
dc.identifierhttp://hdl.handle.net/11447/4475
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/6302779
dc.description.abstractThe use of positron emission tomography with computed tomography (PET/CT) for adult cancer patients is widespread, however, its use in pediatric patients is limited by fear of radiation, monetary cost and lack of awareness of its greater sensitivity in the evaluation of some types of tumors. Ewing's sarcoma is one of the primary pediatric malignancies in which PET/CT with 18F-labeled fluorodeoxyglucose (18F-FDG) has demonstrated greater sensitivity in the evaluation of bone metastases compared to scintigraphy, as well as in the evaluation of treatment response. We report a 13 years old female consulting for retrosternal pain. A chest CT scan showed an infiltrating mass originating in the sternum. A biopsy confirmed the presence of an Ewing sarcoma. The tumor was staged with PET/CT which showed multiple bone lesions not visible in previous studies.
dc.languagees
dc.subjectBone marrow
dc.subjectFluorodeoxyglucose F18
dc.subjectPositron Emission Tomography Computed Tomography
dc.subjectRadionuclide Imaging
dc.subjectSarcoma
dc.subjectEwing
dc.titleActualización en el uso del PET/CT en sarcoma de Ewing, a propósito de un caso
dc.typeArticle


Este ítem pertenece a la siguiente institución